Strategic pan-European approach to combat antimicrobial resistance
Antimicrobial resistance (AMR) causes numerous losses of lives worldwide. Antibiotic treatments need stratification to improve patient outcomes and limit the impact of AMR. The EU-funded VALUE-Dx project aims to develop policy and regulatory recommendations and understand value indicators and barriers for the adoption of community-acquired acute respiratory tract infections (CA-ARTI) diagnostics. The consortium of 6 in vitro diagnostic companies and 20 non-industry partners will define clinical algorithms and user requirements for CA-ARTI diagnostic tests. The value of diagnostics will be tested and demonstrated using pan-European clinical and laboratory research infrastructure, employing the innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeIMI2-RIA - Research and Innovation action
02215 Boston Ma